Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase
Authors:
- 15 November 2018
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 75 (3) , 409-416
Abstract
Statins represent an effective treatment for hyperlipidaemia. Immune-mediated necrotising myopathy (IMNM), a form of statin myopathy, has recently been described, and is characterized by elevated creatine kinase, presence of antibodies against HMG-CoA and no improvement after drug discontinuation, even with immunosuppressive treatment. Information on IMNM is mainly from case reports and small case series. Therefore, all reported cases of IMNM in VigiBase, the WHO global database of individual case safety reports (ICSRs) including the underlying reporting patterns, were analysed to characterize more detailed this adverse drug reaction.Keywords
This publication has 30 references indexed in Scilit:
- Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New DrugsPharmacy, 2018
- Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodiesRheumatology, 2016
- 2016 ESC/EAS Guidelines for the Management of DyslipidaemiasEuropean Heart Journal, 2016
- Statin-Associated Autoimmune MyopathyNew England Journal of Medicine, 2016
- Immune-mediated necrotising myopathy linked to statin useThe Lancet, 2015
- Clinical Features and Treatment Outcomes of Necrotizing Autoimmune MyopathyJAMA Neurology, 2015
- Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathyArthritis & Rheumatism, 2010
- VigiBase, the WHO Global ICSR Database System: Basic FactsDrug Information Journal, 2008
- Prevalence of Musculoskeletal Pain and Statin UseJournal of General Internal Medicine, 2008
- Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering DrugsJAMA, 2004